Back to News
May 1, 2026 4:10 PM

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the closing of its initial public offering (IPO) of an aggregate 19,166,667 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 2,500,000 additional shares, at IPO price of $18.00 per share. All of the shares of common stock were offered by Avalyn.

The aggregate gross proceeds from the offering of the initial shares and the additional shares described above, before deducting underwriting discounts and commissions and other offering expenses, were $345 million. Avalyn's ...